OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Approved and emerging Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia
Alycia Hatashima, Mehdi Karami, Mazyar Shadman
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 13, pp. 1545-1557
Closed Access | Times Cited: 7
Alycia Hatashima, Mehdi Karami, Mazyar Shadman
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 13, pp. 1545-1557
Closed Access | Times Cited: 7
Showing 7 citing articles:
Pirtobrutinib: A New Hope for patients with BTK-inhibitor refractory lymphoproliferative disorders
Philip A. Thompson, Constantine S. Tam
Blood (2023)
Open Access | Times Cited: 26
Philip A. Thompson, Constantine S. Tam
Blood (2023)
Open Access | Times Cited: 26
Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy
Eman M. Abdo, Imad Ajib, Jason El Mounzer, et al.
Inflammation Research (2025) Vol. 74, Iss. 1
Closed Access | Times Cited: 1
Eman M. Abdo, Imad Ajib, Jason El Mounzer, et al.
Inflammation Research (2025) Vol. 74, Iss. 1
Closed Access | Times Cited: 1
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
David Yin-wei Lin, Amy H. Andreotti
PLoS ONE (2023) Vol. 18, Iss. 8, pp. e0290872-e0290872
Open Access | Times Cited: 12
David Yin-wei Lin, Amy H. Andreotti
PLoS ONE (2023) Vol. 18, Iss. 8, pp. e0290872-e0290872
Open Access | Times Cited: 12
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 5, pp. 2949-2970
Open Access | Times Cited: 3
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 5, pp. 2949-2970
Open Access | Times Cited: 3
Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia
Shih‐Shih Chen, Nicholas Chiorazzi
Hematological Oncology (2023) Vol. 41, Iss. S1, pp. 119-128
Open Access | Times Cited: 4
Shih‐Shih Chen, Nicholas Chiorazzi
Hematological Oncology (2023) Vol. 41, Iss. S1, pp. 119-128
Open Access | Times Cited: 4
Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment
Benjamin Greenberg
Neurologic Clinics (2023) Vol. 42, Iss. 1, pp. 155-163
Closed Access | Times Cited: 2
Benjamin Greenberg
Neurologic Clinics (2023) Vol. 42, Iss. 1, pp. 155-163
Closed Access | Times Cited: 2
A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients
Ja Min Byun, Junghoon Shin, Sang‐A Kim, et al.
Cancer Research and Treatment (2023) Vol. 56, Iss. 2, pp. 675-680
Open Access
Ja Min Byun, Junghoon Shin, Sang‐A Kim, et al.
Cancer Research and Treatment (2023) Vol. 56, Iss. 2, pp. 675-680
Open Access
